Bio-Rad研讨会：研究人员使用 ProteOn? XPR36 系统研究癌症、阿尔茨海默病和其他疾病的潜在机制
Bio-Rad研讨会：研究人员使用 ProteOn? XPR36 系统研究癌症、阿尔茨海默病和其他疾病的潜在机制
发布时间： 2012年9月25日
加利福尼亚州赫拉克勒斯 — 2012 年 9 月 25 日 — Bio-Rad 实验室公司宣布扩展蛋白质功能部门正在进行的 ProteOn 网络研讨会系列，该系列展示了利用 ProteOn XPR36 蛋白质相互作用阵列系统的最新癌症和疾病研究，该系统是一种使用表面等离子体共振 （SPR） 生成丰富、无标记动力学结合数据的仪器。先前提出的主题包括使用SPR鉴定和表征与癌症相关的磷酸肌醇信号脂质，以及旨在了解与阿尔茨海默病等神经退行性疾病相关的蛋白质错误折叠，聚集和组织沉积的研究。
“网络研讨会介绍了SPR技术在药物发现工作流程中的最新应用，并为仪器的软件和硬件提供了有价值的更新，”瑞士罗氏Glycart抗体工程组负责人Ralf J. Hosse博士说。
癌症和阿尔茨海默病应用
在 2012 年 7 月的网络研讨会上，英国曼彻斯特帕特森癌症研究所的 Lily Sommer 博士描述了使用 ProteOn XPR36 系统鉴定和表征新型磷酸肌醇结合蛋白的方法。磷酸肌醇是信号脂质，其失调与癌症有关。这些研究是使用 Bio-Rad 的 ProteOn 脂质体捕获试剂盒进行的，该试剂盒使用 DNA 杂交选择性捕获脂质体以检测磷酸肌醇-蛋白质相互作用。
意大利米兰马里奥·内格里研究所的Marco Gobbi主持了一场题为“SPR在研究淀粉样蛋白肽和蛋白质中的新应用”的网络研讨会。他讨论了用于突变分析和研究抗淀粉样蛋白候选药物效果的新型SPR筛选应用。这项工作的结果于2012年6月发表在《生物化学杂志》上。
越来越多的疾病现在与特定蛋白质的错误折叠、聚集和组织沉积有关，例如阿尔茨海默病。淀粉样蛋白-β （A?） 肽的可溶性低聚物在阿尔茨海默病的发病机制中起关键作用，但其难以捉摸的性质使检测具有挑战性。Gobbi和他的团队证明，SPR测量对于淀粉样纤维伸长的动力学分析和可溶性低聚物质的检测特别有用，这是其他技术无法实现的。
SPR上的最好实践
网络研讨会系列以会议拉开序幕，该会议侧重于以色列魏茨曼科学研究所的Gideon Schreiber教授制定的指南，为研究人员提供如何最好地执行无标记相互作用分析的建议。Schreiber博士在无标签领域享有盛誉，并主持了许多关于这一主题的会议。
药物发现和开发应用
以色列 Bio-Rad Haifa 应用团队经理 Dalia Shezifi 博士专注于与脂质体结合的小分子和肽的无标记分析。她的工作展示了ProteOn脂质体捕获试剂盒如何用于解决药物开发中的重要问题，例如在估计新药的肠道吸收率时小分子药物与脂质体的结合。
在总结本系列文章时，Bio-Rad 现场应用专家 Gary Ross 介绍了如何使用 ProteOn 系统在一次 45 分钟的实验中进行抗体定量和全蛋白质动力学分析。对于参与抗体筛选的研究人员来说，此应用程序是一项重要进展，因为它在单个平台上的单个实验中提供了丰富的数据，从而节省了工作台时间。
“这些演讲是激发未来可能进行的新想法和检测的好方法，”瑞典KTH皇家理工学院的博士生Johan Nilvebrant说。
秋季会，新系列
Bio-Rad 的下一个 SPR 网络研讨会系列将于今年秋季举行，将于 9 月 25 日拉开帷幕，意大利赫兰扎诺 DiaSorin 研究中心的研究科学家 Carlotta Chiappa 博士将介绍用于开发艰难梭菌诊断测试的抗体筛选。10 月，Bio-Rad 应用科学家 Jonathan Popplewell 博士将举办一场网络研讨会，重点介绍 SPR 数据处理和下游分析的最佳实践。斯坦福大学医学院博士后研究员Lisa Scalfone博士将讨论ProteOn XPR36系统如何在新的工作流程中用于开发针对流感病毒的抗体。秋季系列的最后一位演讲者，捷克共和国布拉格微生物研究所的博士后研究员Ladislav Bumba博士将讨论细菌毒素与细菌发病机制中靶细胞分子相互作用的分析。
Bio-Rad Laboratories, Inc. Release: Researchers Use the ProteOn? XPR36 System to Study the Mechanisms Underlying Cancer, Alzheimer's Disease, and Other Conditions
Published: Sep 25, 2012
Hercules, CA — September 25, 2012 — Bio-Rad Laboratories, Inc. announces the extension of the Protein Function Division’s ongoing ProteOn webinar series, which showcases the latest cancer and disease research utilizing the ProteOn XPR36 protein interaction array system, an instrument that uses surface plasmon resonance (SPR) to generate rich, label-free kinetic binding data. Previously presented topics include the use of SPR for the identification and characterization of phosphoinositide signaling lipids that have been linked to cancer and in studies aimed at understanding protein misfolding, aggregation, and tissue deposition associated with neurodegenerative conditions such as Alzheimer’s disease.
“The webinars introduced the latest applications of SPR technology for drug discovery workflows and provided valuable updates on the instrument’s software and hardware,” said Dr Ralf J. Hosse, Antibody Engineering Group Leader at Roche Glycart in Switzerland.
Cancer and Alzheimer’s Disease Applications
In a July 2012 webinar, Dr Lily Sommer of the Paterson Institute for Cancer Research in Manchester, U.K., described the identification and characterization of novel phosphoinositide-binding proteins using the ProteOn XPR36 system. Phosphoinositides are signaling lipids whose misregulation has been linked to cancer. The studies were undertaken using Bio-Rad’s ProteOn liposome capturing kit, which uses DNA hybridization to selectively capture liposomes to detect phosphoinositide-protein interactions.
Marco Gobbi of the Mario Negri Institute in Milan, Italy hosted a webinar session titled “Novel Applications of SPR to Study Amyloidogenic Peptides and Proteins.” He discussed novel SPR screening applications for both mutation analysis and investigating the effects anti-amyloidogenic drug candidates. The results of this work were published in the Journal of Biological Chemistry in June 2012.
An increasing number of diseases are now being associated with misfolding, aggregation, and tissue deposition of specific proteins, such as in Alzheimer’s disease. Soluble oligomers of the amyloid-? (A?) peptide play a key role in the pathogenesis of Alzheimer’s disease, but their elusive nature makes detection challenging. Gobbi and his team demonstrated that SPR measurements can be particularly useful for the kinetic analysis of the elongation of amyloid fibrils and the detection of soluble oligomeric species, which cannot be achieved by other techniques.
Best Practices in SPR
The webinar series kicked off with a session that focused on guidelines developed by Professor Gideon Schreiber of the Weizmann Institute of Science in Israel advising researchers on how to best perform label-free interaction analysis. Dr Schreiber is well known in the label-free field and has hosted and chaired many conferences on this topic.
Drug Discovery and Development Applications
Dr Dalia Shezifi, manager of the Bio-Rad Haifa Applications Team in Israel, focused on label-free analysis of small molecules and peptides binding to liposomes. Her work demonstrated how the ProteOn liposome capturing kits have been used to address important issues in drug development, such as the binding of small molecule drugs to liposomes when estimating the intestinal absorptivity of new drugs.
To conclude the series, Gary Ross, a Bio-Rad field application specialist, described how the ProteOn system was used to perform antibody quantification and full protein kinetic analysis in a single 45-minute experiment. This application is an important advance for researchers involved in antibody screening, as it provides rich data in a single experiment on a single platform, saving bench time.
“The presentations were a good way to inspire new ideas and assays that may be performed in the future,” said Johan Nilvebrant, a PhD student at the KTH Royal Institute of Technology in Sweden.
New Season, New Series
Bio-Rad’s next SPR webinar series will take place this fall, kicking off on Sept. 25 with a presentation by Dr Carlotta Chiappa, a research scientist at the DiaSorin Research Center in Geranzano, Italy, on antibody screening for the development of a diagnostic test for Clostridium difficile. In October, Dr Jonathan Popplewell, a Bio-Rad application scientist, will present a webinar focusing on best practices for SPR data processing and downstream analysis. Dr Lisa Scalfone, a postdoctoral researcher at the Stanford University School of Medicine, will talk about how the ProteOn XPR36 system was used in a novel workflow to develop antibodies against the influenza virus. The last speaker in the fall series, Dr Ladislav Bumba, a postdoctoral researcher at the Institute of Microbiology in Prague, Czech Republic, will discuss the analysis of the interactions of bacterial toxins with target cell molecules in bacterial pathogenesis.
厂家名称
Bio-Rad Laboratories, 由 David Schwartz 先生和他的妻子化学家Alice Schwartz 于 1957 年创建，总部位于加州 Hercules。 一直致力于为医疗健康领域提供创新型的实用产品，以帮...